Day: May 20, 2025

Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera® (ceftobiprole medocaril for injection) is now commercially available in the United States through Basilea’s partner Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA). Zevtera is used in hospitals for the treatment of bacterial infections, such as those caused by Staphylococcus aureus bacteria, including methicillin-resistant strains (MRSA). It is the only advanced-generation cephalosporin approved by the United States Food and Drug Administration (FDA) for the treatment of adult patients with Staphylococcus aureus bacteremia (SAB),...

The net asset value (NAV) of EfTEN United Property Fund units was 11,53 euros at the end of April, increasing by 1,6% per month. The fund earned a net profit of 449 thousand euros in April and a net profit of 1,15 million euros during the four months of 2025 (last year at the same time 331 thousand euros). If the fund’s investment in EfTEN Real Estate Fund AS shares were recorded on the basis of its net asset value, the NAV of EfTEN United Property Fund would be 11,58 euros, increasing by 1,4% per month.  In April, the fund received the biggest profit (274 thousand euros) from its investment in the development company Invego Uus-Järveküla OÜ. During the month the last terraced houses of the development’s second stage were transferred to clients in the Uus-Järveküla (real right agreements were concluded), from which the company earned...

Global leaders in sustainable agricultural innovation to develop biological solutions to reduce food waste Ghent, BELGIUM, and Philadelphia, USA, May 20, 2025 (GLOBE NEWSWIRE) — Press release Ghent, BELGIUM, and Philadelphia, USA – 20 May 2025, 07.00 CEST – An estimated 14 percent of produce is lost between harvest and retail*, in part due to spoilage from mold and rot. To help address this global challenge, Biotalys (Euronext – BTLS), an agricultural technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, and AgroFresh Solutions, Inc., a global leader in post-harvest solutions for fresh produce, today announced a new collaboration to develop and commercialize sustainable biological fungicides for post-harvest use. Fungicides are already essential to protect fresh produce...

The collaboration will provide GF with access to A*STAR’s state-of-the-art R&D facilities, capabilities and technical support for technology development and workforce skills enhancement in advanced packaging SINGAPORE, May 19, 2025 (GLOBE NEWSWIRE) — GlobalFoundries (Nasdaq: GFS) (GF) today announced plans to expand its capabilities in advanced packaging through a new Memorandum of Understanding (MOU) signed with the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector research and development (R&D) agency. Advanced packaging has become a key R&D priority for the semiconductor industry amid growing demand for artificial intelligence (AI) and other data-intensive applications ranging from high performance data computing and datacenters to 5G / 6G communication and more. To meet these...

BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the pricing of a follow-on offering of 2,000,000 units, with each unit consisting of one ordinary share (or pre-funded warrant in lieu thereof), one Series A warrant to purchase one ordinary share, and one Series B warrant to purchase one ordinary share for gross proceeds of approximately $4.0 million. Each unit is being sold at an effective offering price of $2.00 per unit. Each Series A warrant will be immediately exercisable at an exercise price of $2.00 per share and will expire five years from the date of issuance. Each Series B warrant will be immediately exercisable at an exercise price...